CMA reaccuses Pfizer and Flynn of excessive pricing

The UK’s Competition and Markets Authority has accused Pfizer and Flynn Pharma of charging unfairly high prices for an anti-epilepsy medication, 17 months after an appellate court ordered the agency to redo parts of its initial probe into the drugmakers.


Get unlimited access to all Global Competition Review content